A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Haematological Malignancies Clinical Trial

Official title: A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Status Terminated

Clinical Trial Summary

EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completion.

Clinical Trial Description

The goal of this research study is to investigate for the first time the safety and tolerability of a new drug (AS703569), called an aurora kinase inhibitor, being tested to treat blood cancers in patients with different blood cancers. The research study will also assess how the body breaks down AS703569 and what changes occur in the blood after oral doses of AS703569. It will also look to see if there is any improvement in your blood cancer. The use of AS703569 in this study is experimental. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Haematological Malignancies
• Hematologic Neoplasms
• Neoplasms

• NCT number: NCT01080664
• Study type: Interventional
• Source: EMD Serono
• Status: Terminated
• Phase: Phase 1
• Start date: December 2006
• Completion date: August 2011